
Colin W Howden

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7653720/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Effect of Food on the Pharmacokinetics of the Potassiumâ€Competitive Acid Blocker Vonoprazan. Clinical Pharmacology in Drug Development, 2022, 11, 278-284.	1.6	20
2	Systematic review with metaâ€analysis: oneâ€year outcomes of gastric peroral endoscopic myotomy for refractory gastroparesis. Alimentary Pharmacology and Therapeutics, 2022, 55, 168-177.	3.7	21
3	Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data. Digestive Diseases and Sciences, 2022, 67, 4382-4386.	2.3	3
4	A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure. Journal of Clinical Pharmacology, 2022, 62, 801-811.	2.0	9
5	Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects. American Journal of Gastroenterology, 2022, 117, 1158-1161.	0.4	27
6	A Message from the Editors. Alimentary Pharmacology and Therapeutics, 2022, 55, 4-5.	3.7	0
7	Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. Gut, 2021, 70, gutjnl-2020-320690.	12.1	17
8	Estimate of Refractory Reflux Disease in the United States. Journal of Clinical Gastroenterology, 2021, 55, 842-850.	2.2	10
9	A Patient with Eosinophilic Esophagitis and Herpes Simplex Esophagitis: A Case Report and Literature Review. Case Reports in Gastrointestinal Medicine, 2021, 2021, 1-3.	0.3	0
10	Efficacy and safety of supplemental intravenous lidocaine for sedation in gastrointestinal endoscopic procedures: systematic review and meta-analysis of randomized controlled trials. Gastrointestinal Endoscopy, 2021, 93, 1241-1249.e6.	1.0	5
11	Role of routine second-look endoscopy in patients with acute peptic ulcer bleeding: meta-analysis of randomized controlled trials. Gastrointestinal Endoscopy, 2021, 93, 1228-1237.e5.	1.0	4
12	Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies. Gastroenterology, 2021, 160, 2588-2590.e7.	1.3	14
13	A change at the top. Alimentary Pharmacology and Therapeutics, 2021, 54, 6-6.	3.7	0
14	Alarming Trends in Opioid Use Among Patients With GERD. American Journal of Gastroenterology, 2021, Publish Ahead of Print, 2146-2147.	0.4	0
15	Efficacy of empiric esophageal dilation in patients with non-obstructive dysphagia: systematic review and meta-analysis. Scandinavian Journal of Gastroenterology, 2021, 56, 1-6.	1.5	1
16	Review article: potassiumâ€competitive acid blockers for the treatment of acidâ€related disorders. Alimentary Pharmacology and Therapeutics, 2021, 53, 794-809.	3.7	53
17	S1387 A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race and Disease Status on Exposure. American Journal of Gastroenterology, 2021, 116, S636-S637.	0.4	0
18	Editorial: the neverâ€ending story— <i>Helicobacter pylori</i> and peptic ulcer disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 1350-1351.	3.7	1

#	Article	IF	CITATIONS
19	S374â€fPatient Burden and Treatment Goals in the Management of Erosive Esophagitis in the United States: Results From the Study of Acid-Related Disorders (SOARD). American Journal of Gastroenterology, 2021, 116, S163-S164.	0.4	0
20	Recent Developments Pertaining to H. pylori Infection. American Journal of Gastroenterology, 2021, 116, 1-3.	0.4	13
21	Insights on the Potential Use of Potassium-Competitive Acid Blockers in Erosive Esophagitis. Gastroenterology and Hepatology, 2021, 17, 178-180.	0.1	0
22	Editorial: pharmacodynamics of potassium ompetitive acid blockers: comparing apples with apples—and with oranges. Alimentary Pharmacology and Therapeutics, 2021, 53, 190-191.	3.7	2
23	One Step Forward But Room for Improvement in Reducing Risk of Gastric Cancer by Curing Helicobacter pylori Infection. Gastroenterology, 2020, 158, 466-467.	1.3	3
24	No Association Linking Short-Term Proton Pump Inhibitor Use to Dementia: Systematic Review and Meta-analysis of Observational Studies. American Journal of Gastroenterology, 2020, 115, 671-678.	0.4	27
25	Controversies Around Measuring Drug Toxicity: US Food and Drug Administration and Gastrointestinal Perspectives. Gastroenterology, 2020, 158, 22-27.	1.3	2
26	Underwater vs conventional endoscopic mucosal resection in the management of colorectal polyps: a systematic review and meta-analysis. Endoscopy International Open, 2020, 08, E1264-E1272.	1.8	15
27	Update on the Management of Helicobacter pylori Infection. Current Treatment Options in Gastroenterology, 2020, 18, 476-487.	0.8	33
28	Sa1257 COMPARISON OF PER-ORAL ENDOSCOPIC MYOTOMY AND PNEUMATIC DILATION IN THE MANAGEMENT OF ACHALASIA: SYSTEMATIC REVIEW AND META-ANALYSIS. Gastrointestinal Endoscopy, 2020, 91, AB135-AB136.	1.0	0
29	Efficacy and safety of tranexamic acid in acute upper gastrointestinal bleeding: meta-analysis of randomised controlled trials. Scandinavian Journal of Gastroenterology, 2020, 55, 1390-1397.	1.5	7
30	Prophylactic hemoclips in prevention of delayed post-polypectomy bleeding for ≥ 1 cm colorectal polyps: meta-analysis of randomized controlled trials. Endoscopy International Open, 2020, 08, E1102-E1110.	1.8	3
31	PPIs and GI Cancers: Impeached But Likely to Be Acquitted. American Journal of Gastroenterology, 2020, 115, 683-684.	0.4	1
32	Systematic review and meta-analysis: monopolar hemostatic forceps with soft coagulation in the treatment of peptic ulcer bleeding. European Journal of Gastroenterology and Hepatology, 2020, 32, 678-685.	1.6	4
33	Sa1284 EFFICACY AND SAFETY OF PER-ORAL ENDOSCOPIC MYOTOMY (POEM) AFTER FAILED HELLER MYOTOMY: SYSTEMATIC REVIEW AND META-ANALYSIS Gastrointestinal Endoscopy, 2020, 91, AB148-AB149.	1.0	0
34	Mo1686 ROLE OF PROPHYLACTIC HEMOCLIP PLACEMENT IN PREVENTION OF DELAYED POST-POLYPECTOMY BLEEDING FOR LARGE COLON POLYPS: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Gastrointestinal Endoscopy, 2020, 91, AB450-AB451.	1.0	0
35	Mo1719 UNDERWATER VS. CONVENTIONAL ENDOSCOPIC MUCOSAL RESECTION OF COLORECTAL POLYPS:SYSTEMATIC REVIEW AND META-ANALYSIS. Gastrointestinal Endoscopy, 2020, 91, AB464.	1.0	0
36	Efficacy and safety of peroral endoscopic myotomy in the management of recurrent achalasia after failed Heller myotomy: a systematic review and meta-analysis. Annals of Gastroenterology, 2020, 34, 155-163.	0.6	7

#	Article	IF	CITATIONS
37	Emerging Regimens for H. pylori Infection Should Enhance Efficacy and Circumvent Resistance. Digestive Diseases and Sciences, 2019, 64, 2691-2692.	2.3	1
38	580 The Safety and Efficacy of Proton-Pump Inhibitors (PPI) Usage in Critical Care Patients for Stress Ulcer Prophylaxis: A Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology, 2019, 114, S333-S333.	0.4	0
39	Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis. BMJ, The, 2019, 367, 16483.	6.0	36
40	Inpatient Outcomes for Gastrointestinal Bleeding Associated With Percutaneous Coronary Intervention. Journal of Clinical Gastroenterology, 2019, 53, 120-126.	2.2	3
41	The Association Between Proton Pump Inhibitor Use With Acute Kidney Injury and Chronic Kidney Disease. Journal of Clinical Gastroenterology, 2018, 52, 468-476.	2.2	20
42	Proton pump inhibitors and oesophageal cancer: Flawed methodology and false alarms. Cancer Epidemiology, 2018, 54, 137-138.	1.9	0
43	Response to Hsu et al American Journal of Gastroenterology, 2018, 113, 143.	0.4	0
44	Response to Marlicz et al. American Journal of Gastroenterology, 2018, 113, 781.	0.4	1
45	Unusual Presentation of Duodenal Ulcer Presenting with Duodenal Intussusception. ACG Case Reports Journal, 2018, 5, e25.	0.4	9
46	Clarifying the Houston Consensus on Helicobacter pylori. Clinical Gastroenterology and Hepatology, 2018, 16, 2003-2004.	4.4	0
47	On-Demand Therapy with Proton Pump Inhibitors for Maintenance Treatment of Nonerosive Reflux Disease or Mild Erosive Esophagitis: A Systematic Review and Meta-Analysis. Gastroenterology Research and Practice, 2018, 2018, 1-10.	1.5	20
48	Deliberate Ingestion of Metallic Objects: Wait, Watch, and They Shall Pass. American Journal of Gastroenterology, 2018, 113, S1074.	0.4	0
49	The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders. Gastroenterology and Hepatology, 2018, 14, 169-175.	0.1	4
50	ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology, 2017, 112, 212-239.	0.4	1,084
51	Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention. Current Problems in Cardiology, 2017, 42, 146-164.	2.4	51
52	The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs, 2017, 77, 547-561.	10.9	62
53	Proton Pump Inhibitors and the Possible Development of Hepatic Encephalopathy in Cirrhotic Patients: True Association or Residual Confounding?. Gastroenterology, 2017, 152, 2076.	1.3	9
54	Complications of Proton Pump Inhibitor Therapy. Gastroenterology, 2017, 153, 35-48.	1.3	353

#	Article	IF	CITATIONS
55	ACG and CAG Clinical Guideline: Management of Dyspepsia. American Journal of Gastroenterology, 2017, 112, 988-1013.	0.4	431
56	Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2017, 112, 1495-1505.	0.4	83
57	Open vs Intact Proton Pump Inhibitor Capsules for Treatment of Marginal Ulcers. Clinical Gastroenterology and Hepatology, 2017, 15, 1479-1480.	4.4	1
58	American Gastroenterological Association Drug Development Conferences: A Model for Future Collaborations. Clinical Gastroenterology and Hepatology, 2017, 15, 1195-1196.	4.4	1
59	Response to Georgopoulos et al American Journal of Gastroenterology, 2017, 112, 1169-1170.	0.4	2
60	Proton pump inhibitors and chronic kidney disease. Kidney International, 2017, 92, 515.	5.2	2
61	Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2017, 29, 1109-1117.	1.6	32
62	Proton Pump Inhibitors and Risk of Rhabdomyolysis. Drug Safety, 2017, 40, 61-64.	3.2	20
63	Does Urgent Colonoscopy Improve Outcomes in the Management of Lower Gastrointestinal Bleeding?. American Journal of the Medical Sciences, 2017, 353, 298-306.	1.1	28
64	Are proton pump inhibitors a threat for spontaneous bacterial peritonitis and hepatic encephalopathy in cirrhosis? Not so fast. Hepatology, 2017, 65, 393-393.	7.3	3
65	Meta-analysis of the performance of ultrathin vs. standard colonoscopes. Endoscopy, 2017, 49, 351-358.	1.8	13
66	Response to Dai et al American Journal of Gastroenterology, 2016, 111, 1657-1658.	0.4	0
67	Mesalamine Does Not Help Prevent Recurrent Acute Colonic Diverticulitis: Meta-Analysis of Randomized, Placebo-Controlled Trials. American Journal of Gastroenterology, 2016, 111, 579-581.	0.4	20
68	Update on the Diagnosis and Management of Helicobacter pylori Infection in Adults. Journal of Clinical Gastroenterology, 2015, 49, 461-467.	2.2	5
69	Systematic review and meta-analysis of the possible association between pharmacological gastric acid suppression and spontaneous bacterial peritonitis. European Journal of Gastroenterology and Hepatology, 2015, 27, 1327-1336.	1.6	35
70	Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy. Gut, 2014, 63, 720-726.	12.1	26
71	Response of Chronic Cough to Acid-Suppressive Therapy in Patients With Gastroesophageal Reflux Disease. Chest, 2013, 143, 605-612.	0.8	144
72	Response to Nahon et al. and Marmo et al American Journal of Gastroenterology, 2013, 108, 1534-1535.	0.4	0

#	Article	IF	CITATIONS
73	High-dose versus low-dose intravenous proton pump inhibitor treatment for bleeding peptic ulcers. Expert Review of Gastroenterology and Hepatology, 2012, 6, 675-677.	3.0	1
74	Recent Safety Concerns With Proton Pump Inhibitors. Journal of Clinical Gastroenterology, 2012, 46, 93-114.	2.2	82
75	Regurgitation Is Less Responsive to Acid Suppression Than Heartburn in Patients With Gastroesophageal Reflux Disease. Clinical Gastroenterology and Hepatology, 2012, 10, 612-619.	4.4	102
76	The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut, 2012, 61, 970-976.	12.1	532
77	Systematic Review of the Epidemiology of Complicated Peptic Ulcer Disease: Incidence, Recurrence, Risk Factors and Mortality. Digestion, 2011, 84, 102-113.	2.3	373
78	Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut, 2011, 60, 1473-1478.	12.1	59
79	Long-Term Tegaserod Treatment for Dysmotility-like Functional Dyspepsia: Results of Two Identical 1-year Cohort Studies. Digestive Diseases and Sciences, 2010, 55, 684-697.	2.3	18
80	PPIs and Clopidogrel: The Band Plays On……………. American Journal of Gastroenterology, 2010, 105, 2438-2439.	0.4	6
81	Antiplatelet therapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. Key messages for clinical practice. Polish Archives of Internal Medicine, 2010, 120, 143-147.	0.4	0
82	Update on Dual Delayed-Release PPI Formulations. Gastroenterology and Hepatology, 2010, 6, 417-9.	0.1	3
83	Control of 24-hour Intragastric Acidity With Morning Dosing of Immediate-release and Delayed-release Proton Pump Inhibitors in Patients With GERD. Journal of Clinical Gastroenterology, 2009, 43, 323-326.	2.2	20
84	Resident Physician's Knowledge of Risk Factors for Upper Gastrointestinal Complications From NSAIDs. American Journal of Therapeutics, 2009, 16, 404-411.	0.9	2
85	Potential adverse effects of proton pump inhibitors. Current Gastroenterology Reports, 2008, 10, 208-214.	2.5	54
86	Meta-analysis: Sequential Therapy Appears Superior to Standard Therapy for Helicobacter pylori Infection in Patients Naive to Treatment. Annals of Internal Medicine, 2008, 148, 923.	3.9	254
87	Is There a Dark Side to Long-term Proton Pump Inhibitor Therapy?. American Journal of Therapeutics, 2008, 15, 536-542.	0.9	35
88	Use of Gastroprotection in Patients Discharged From Hospital on Nonsteroidal Anti-inflammatory Drugs. American Journal of Therapeutics, 2008, 15, 444-449.	0.9	9
89	Errors in a Meta-analysis of Treatments for Helicobacter pylori Infection. Annals of Internal Medicine, 2008, 149, 686.	3.9	1
90	On-Demand Therapy for Gastroesophageal Reflux Disease. American Journal of Gastroenterology, 2007. 102. 642-653.	0.4	66

#	Article	IF	CITATIONS
91	Proton Pump Inhibitor Therapy for Peptic Ulcer Bleeding: Cochrane Collaboration Meta-analysis of Randomized Controlled Trials. Mayo Clinic Proceedings, 2007, 82, 286-296.	3.0	107
92	Pharmacologic treatment of peptic ulcer bleeding. Current Treatment Options in Gastroenterology, 2007, 10, 134-142.	0.8	13
93	Should we give a PPI IV before endoscopy in patients with upper GI bleeding?. Polish Archives of Internal Medicine, 2007, 117, 210-212.	0.4	0
94	Practice patterns for managing Helicobacter pylori infection and upper gastrointestinal symptoms. American Journal of Managed Care, 2007, 13, 37-44.	1.1	11
95	Early infusion of high-dose omeprazole before endoscopy reduced the need for endoscopic therapy. ACP Journal Club, 2007, 147, 18.	0.1	0
96	Proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 1763-1765.	2.8	8
97	Immediate-Release Omeprazole/Sodium Bicarbonate. Gastroenterology and Hepatology, 2006, 2, 386.	0.1	0
98	Some Observations on PPI Therapy for Bleeding Ulcer. Gastroenterology and Hepatology, 2006, 2, 571-577.	0.1	0
99	Response to Monge and Montes. Journal of Clinical Gastroenterology, 2005, 39, 258.	2.2	0
100	Who???s Afraid of the Big Bad GERD?. Journal of Clinical Gastroenterology, 2004, 38, 731-732.	2.2	0
101	Is no NSAID a good NSAID? approaches to NSAID-associated upper gastrointestinal disease. Current Gastroenterology Reports, 2004, 6, 447-453.	2.5	10
102	A National Survey of Primary Care Physicians??? Perceptions and Practices Related to Helicobacter pylori Infection. Journal of Clinical Gastroenterology, 2004, 38, 326-331.	2.2	30
103	Patient Anxiety and Elective Gastrointestinal Endoscopy. Journal of Clinical Gastroenterology, 2004, 38, 35-40.	2.2	65
104	A scheduled second endoscopy 16 to 24 hours after initial endoscopic hemostasis reduced recurrent peptic ulcer bleeding. ACP Journal Club, 2004, 140, 11.	0.1	1
105	Universal precautions guideline: self-reported compliance by gastroenterologists and gastrointestinal endoscopy nurses-a decade's lack of progress. American Journal of Gastroenterology, 2003, 98, 2420-2423.	0.4	24
106	Knowledge, Attitudes, and Practice Styles of North American Pediatric Gastroenterologists:Helicobacter pylori Infection. Journal of Pediatric Gastroenterology and Nutrition, 2003, 36, 235-240.	1.8	12
107	Gastroesophageal reflux disease. Journal of Family Practice, 2003, 52, 240-7.	0.2	11
108	Lansoprazole reduced recurrence of ulcer complications in long-term use of low-dose aspirin. ACP Journal Club, 2003, 138, 11.	0.1	2

7

#	Article	IF	CITATIONS
109	Current liver biopsy practices for suspected parenchymal liver diseases in the United States: the evolving role of radiologists. American Journal of Gastroenterology, 2002, 97, 1468-1471.	0.4	44
110	Response to Dr. Longstreth. American Journal of Gastroenterology, 2002, 97, 204-204.	0.4	6
111	Placement of a covered metal stent via gastrostomy for management of malignant duodenocolic fistula with duodenal obstruction. Gastrointestinal Endoscopy, 2002, 55, 937-940.	1.0	5
112	Evidence for Therapeutic Equivalence of Lansoprazole 30mg and Esomeprazole 40mg in the Treatment of Erosive Oesophagitis. Clinical Drug Investigation, 2002, 22, 99-109.	2.2	49
113	Therapeutic Equivalence of Lansoprzole and Esomeprazole. Clinical Drug Investigation, 2002, 22, 415-416.	2.2	Ο
114	Seroprevalence of H. pylori infection and symptoms of upper gastrointestinal tract disease in two groups of health-care workers. Digestive Diseases and Sciences, 2002, 47, 292-297.	2.3	11
115	Assessing and improving doctors' understanding of Helicobacter pylori infection. Romanian Journal of Gastroenterology, 2002, 11, 275-6.	0.3	0
116	Current indications for acid suppressants in Helicobacter pylori -negative ulcer disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2001, 15, 401-412.	2.4	12
117	The Effect of Stimulant Laxatives and Polyethylene Glycol-electrolyte Lavage Solution for Colonoscopy Preparation on Serum Electrolytes and Hemodynamics. Journal of Clinical Gastroenterology, 2001, 32, 238-239.	2.2	17
118	Prophylactic Antibiotic Administration Reduces Sepsis and Mortality in Acute Necrotizing Pancreatitis: A Meta-Analysis. Pancreas, 2001, 22, 28-31.	1.1	173
119	The utility of urgent colonoscopy in the evaluation of acute lower gastrointestinal tract bleeding: a 2-year experience from a single center. American Journal of Gastroenterology, 2001, 96, 1782-1785.	0.4	110
120	Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. American Journal of Gastroenterology, 2001, 96, 1704-1710.	0.4	85
121	An Audit of The Utility of in-Patient Fecal Occult Blood Testing. American Journal of Gastroenterology, 2001, 96, 1256-1260.	0.4	25
122	Differing attitudes toward virtual and conventional colonoscopy for colorectal cancer screening: surveys among primary care physicians and potential patients. American Journal of Gastroenterology, 2001, 96, 887-893.	0.4	83
123	A survey of internal medicine residents' knowledge about Helicobacter pylori infection. American Journal of Gastroenterology, 2000, 95, 1914-1919.	0.4	21
124	Changes in Colorectal Cancer Over A 15-Year Period in A Single United States City. American Journal of Gastroenterology, 2000, 95, 3615-3619.	0.4	22
125	Survey of The Opinions, Knowledge, and Practices of Gastroenterologists Regarding Colorectal Cancer Screening and Use of The Fecal Occult Blood Test. American Journal of Gastroenterology, 2000, 95, 3629-3632.	0.4	37
126	Survey of internal medicine residents' use of the fecal occult blood test and their understanding of colorectal cancer screening and surveillance. American Journal of Gastroenterology, 2000, 95, 2068-2073.	0.4	45

#	Article	IF	CITATIONS
127	Colorectal cancer screening and surveillance practices by primary care physicians: results of a national survey. American Journal of Gastroenterology, 2000, 95, 1551-1556.	0.4	77
128	Meta-analysis of randomized, controlled trials of antibiotic prophylaxis before percutaneous endoscopic gastrostomy. American Journal of Gastroenterology, 2000, 95, 3133-3136.	0.4	170
129	Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. American Journal of Gastroenterology, 2000, 95, 57-61.	0.4	77
130	Diagnostic yield of colonoscopy in patients with a positive fecaloccult blood test. Gastrointestinal Endoscopy, 2000, 52, 820-821.	1.0	0
131	Vitamin B12 Levels During Prolonged Treatment With Proton Pump Inhibitors. Journal of Clinical Gastroenterology, 2000, 30, 29-33.	2.2	102
132	Treatment of Helicobacter pylori Infection. Journal of Clinical Gastroenterology, 2000, 31, 105-106.	2.2	0
133	H. PYLORI ERADICATION IN FUNCTIONAL DYSPEPSIA. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, H27-H27.	2.8	0
134	A Survey of Gastroenterologists' Perceptions and Practices Related to Helicobacter Pylori Infection. American Journal of Gastroenterology, 1999, 94, 3170-3174.	0.4	24
135	Examination of tissue distribution of Helicobacter pylori within columnar-lined esophagus. Digestive Diseases and Sciences, 1999, 44, 1165-1168.	2.3	8
136	No evidence for an association between H. pylori and idiopathic chronic urticaria. Digestive Diseases and Sciences, 1999, 44, 485-486.	2.3	17
137	Metaanalysis of Randomized Controlled Trials of Endoscopic Retrograde Cholangiography and Endoscopic Sphincterotomy for The Treatment of Acute Biliary Pancreatitis. American Journal of Gastroenterology, 1999, 94, 3211-3214.	0.4	164
138	Simplified lansoprazole suspension— a liquid formulation of lansoprazole— effectively suppresses intragastric acidity when administered through a gastrostomy. American Journal of Gastroenterology, 1999, 94, 1813-1817.	0.4	24
139	Prospective, randomized, controlled comparison of the use of polyethylene glycol electrolyte lavage solution in four-liter versus two-liter volumes and pretreatment with either magnesium citrate or bisacodyl for colonoscopy preparation. Gastrointestinal Endoscopy, 1998, 47, 167-171.	1.0	142
140	Guidelines for the management of Helicobacter pylori infection. American Journal of Gastroenterology, 1998, 93, 2330-2338.	0.4	302
141	Changing Trends in Esophageal Cancer: A 15-Year Experience in a Single Center. American Journal of Gastroenterology, 1998, 93, 702-705.	0.4	17
142	A Study of the Prevalence of Helicobacter pylori Infection and Other Markers of Upper Gastrointestinal Tract Disease in Patients With Rosacea. American Journal of Gastroenterology, 1998, 93, 220-222.	0.4	71
143	Gastrointestinal and Hepatic Manifestations of Hereditary Hemorrhagic Telangiectasia. Digestive Diseases, 1998, 16, 169-174.	1.9	37
144	Randomized, controlled study of pretreatment with magnesium citrate on the quality of colonoscopy preparation with polyethylene glycol electrolyte lavage solution. Gastrointestinal Endoscopy, 1997, 46, 541-543.	1.0	69

#	ARTICLE	IF	CITATIONS
145	Randomized controlled trial of rectal tube placement for the management of abdominal distension following colonoscopy. Gastrointestinal Endoscopy, 1997, 46, 444-446.	1.0	11
146	Recurrent Peptic Ulceration. Digestive Diseases, 1997, 15, 92-99.	1.9	2
147	Malignant Transformation in a Duodenal Villous Adenoma of the Afferent Limb of Billroth II Anastomosis. Journal of Clinical Gastroenterology, 1997, 24, 290-291.	2.2	0
148	How many patients must we treat for Helicobacter pylori infection to prevent a recurrent duodenal ulcer hemorrhage?. Gastrointestinal Endoscopy, 1996, 43, 175.	1.0	3
149	Clinical Expressions of Helicobacter pylori Infection. American Journal of Medicine, 1996, 100, 27S-34S.	1.5	71
150	Optimizing acid suppression for treatment of acid-related diseases. Digestive Diseases and Sciences, 1995, 40, 24S-49S.	2.3	79
151	Advances in the therapeutic uses of histamine H2-receptor antagonists. Bailliere's Clinical Gastroenterology, 1993, 7, 81-94.	0.9	1
152	Nonsteroidal antiinflammatory drugs and lower gastrointestinal bleeding. Digestive Diseases and Sciences, 1993, 38, 1619-1623.	2.3	49
153	Prevalence of esophagitis. Digestive Diseases and Sciences, 1992, 37, 1469-1470.	2.3	1
154	Omeprazole did not reduce mortality, rebleeding, surgery, or transfusion required in acute upper gastrointestinal bleeding. ACP Journal Club, 1992, 117, 16.	0.1	0
155	Clinical Pharmacology of Omeprazole. Clinical Pharmacokinetics, 1991, 20, 38-49.	3.5	122
156	Antisecretory therapy and genotoxicity. Digestive Diseases and Sciences, 1991, 36, 545-547.	2.3	13
157	Pharmacodynamic Studies in Normal Volunteers with MDL-899, a New Arteriolar Vasodilator. Journal of Cardiovascular Pharmacology, 1983, 5, 552-556.	1.9	7
158	Pharmacodynamic Studies with a Specific α2-Adrenoceptor Agonist (BHT-933) in Man. Journal of Cardiovascular Pharmacology, 1982, 4, 527-530.	1.9	12